| Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.Lancet HIV | PMID 37494942无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.Muscle Nerve | PMID 37525592无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial.Eur Urol Oncol | PMID 37543464无 PMCID | 2023-Oct | 0.95 | The trial is an oncology, human, randomized, Phase III study with a time-to-event endpoint (recurrence-free survival reported via Cox HR). However, the intervention is purely surgical (en bloc vs conventional resection) with no drug component. Per adjudication rules, a drug-containing intervention is required for eligibility. Therefore, the record is excluded. | 待处理 |
| Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.Epilepsia | PMID 37543865无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).J Urol | PMID 37548555PMC12721658 | 2023-Oct | 0.85 | The record describes a randomized Phase III trial with a time-to-event primary endpoint (disease-free survival). However, the intervention (UGN-102) is a drug-containing gel for local chemoablation, and the study is framed as a comparison of a chemoablation technique versus a surgical procedure (TURBT). The adjudication rules require a 'drug-containing intervention,' but the context and primary analysis emphasize the procedural/ablation aspect, making the drug component not the clear, primary therapeutic modality under test. Therefore, it does not meet the strict criterion for a drug intervention as defined for this cohort. | 待处理 |
| Efficacy and safety of lemborexant in subjects previously treated with placebo for 6 months in a randomized phase 3 study.Sleep Med | PMID 37574610无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized controlled trial of the behavioral intervention for physical activity in multiple sclerosis project: Social cognitive theory variables as mediators.Mult Scler Relat Disord | PMID 37586313无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).Adv Ther | PMID 37603205PMC10499948 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.Leukemia | PMID 37604981PMC10539167 | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.Thorac Cancer | PMID 37609677PMC10569902 | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.Lancet Diabetes Endocrinol | PMID 37619579PMC10522778 | 2023-Oct | 0.90 | The record is a phase 3 randomized trial of adjuvant mitotane versus surveillance in adrenocortical carcinoma with a primary time-to-event endpoint (RFS) and secondary OS, reporting hazard ratios. It meets all eligibility criteria for an original formal result. | 待处理 |
| Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.Gynecol Oncol | PMID 37625235PMC10986425 | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation.Antivir Ther | PMID 37657421无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.Eur J Cancer | PMID 37660438无 PMCID | 2023-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS).Curr Med Res Opin | PMID 37691437无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.Lancet Oncol | PMID 37708912无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.Nat Med | PMID 37709999PMC10579091 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.Lancet Oncol | PMID 37714168无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol | PMID 37739572无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine for the prevention of mucositis induced by platinum-based chemoradiation in head and neck cancer: A phase II study.Clin Nutr ESPEN | PMID 37739730无 PMCID | 2023-Oct | 0.80 | The study is a Phase II randomized trial in head and neck cancer, but it fails several key inclusion criteria: it is not a Phase III/IIIb trial; the intervention (HMB/Arg/Gln) is a nutritional supplement mixture, not a drug; and the endpoints (mucositis incidence, body weight loss) are not time-to-event efficacy outcomes. | 待处理 |
| Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial.Lancet Digit Health | PMID 37775187PMC10921847 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.Nat Med | PMID 37783969PMC10579052 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.Lancet Haematol | PMID 37793771无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.Lancet Haematol | PMID 37793772无 PMCID | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.Autism Res | PMID 37794745无 PMCID | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial.Nat Med | PMID 37814062PMC10579095 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.J Immunother Cancer | PMID 37903590PMC10619123 | 2023-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Posterior cervical foraminotomy versus anterior cervical discectomy for Cervical Brachialgia: the FORVAD RCT.Health Technol Assess | PMID 37929307PMC10641711 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.Health Technol Assess | PMID 37929672PMC10641860 | 2023-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.Lancet | PMID 37499670无 PMCID | 2023-Sep-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).BMC Cancer | PMID 37777738PMC10544147 | 2023-Sep-30 | 0.45 | This is a Phase II randomized trial protocol for radiation therapy (no drug intervention) with toxicity as the primary endpoint, lacking a time-to-event efficacy analysis or original results. | 待处理 |
| Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.BMJ | PMID 37748804PMC10518699 | 2023-Sep-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.Lancet | PMID 37524096PMC10622111 | 2023-Sep-23 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.Vaccine | PMID 37652823无 PMCID | 2023-Sep-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.Arthritis Res Ther | PMID 37723577PMC10506267 | 2023-Sep-18 | 0.95 | The study is a randomized Phase III trial of a drug intervention (upadacitinib) with original results, but it is not in oncology (it is in rheumatology/ankylosing spondylitis) and does not report a time-to-event efficacy endpoint. | 待处理 |
| Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.Arthritis Res Ther | PMID 37715294PMC10503152 | 2023-Sep-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.J Patient Rep Outcomes | PMID 37702920PMC10499766 | 2023-Sep-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial.BMJ Open | PMID 37709311PMC11148698 | 2023-Sep-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.Blood Adv | PMID 37276510PMC10471926 | 2023-Sep-12 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.Blood Adv | PMID 37379264PMC10471938 | 2023-Sep-12 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.J Clin Oncol | PMID 37379502无 PMCID | 2023-Sep-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.Lancet | PMID 37591292无 PMCID | 2023-Sep-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.Sci Rep | PMID 37684299PMC10491626 | 2023-Sep-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.Int J Gynecol Cancer | PMID 37666539无 PMCID | 2023-Sep-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 37516125无 PMCID | 2023-Sep-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dosimetric Evaluation of Organs at Risk From SAVE Protocol.Int J Radiat Oncol Biol Phys | PMID 37023988无 PMCID | 2023-Sep-01 | 0.85 | This is a randomized Phase III trial in human oncology, but the intervention is brachytherapy (non-drug), and the primary outcome reported is dosimetric evaluation of organs at risk, not a time-to-event efficacy endpoint. The abstract mentions no isolated vaginal recurrences, but this is a safety/dosimetric report, not a primary efficacy analysis. | 待处理 |
| Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.Am J Psychiatry | PMID 37132201无 PMCID | 2023-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.J Clin Oncol | PMID 37257143PMC10852366 | 2023-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.J Am Soc Nephrol | PMID 37303085PMC10482062 | 2023-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association Between Biliary Pathogens, Surgical Site Infection, and Pancreatic Fistula: Results of a Randomized Trial of Perioperative Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy.Ann Surg | PMID 37314221PMC10838195 | 2023-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |